These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 25813205)
1. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Niesvizky R; Badros AZ; Costa LJ; Ely SA; Singhal SB; Stadtmauer EA; Haideri NA; Yacoub A; Hess G; Lentzsch S; Spicka I; Chanan-Khan AA; Raab MS; Tarantolo S; Vij R; Zonder JA; Huang X; Jayabalan D; Di Liberto M; Huang X; Jiang Y; Kim ST; Randolph S; Chen-Kiang S Leuk Lymphoma; 2015; 56(12):3320-8. PubMed ID: 25813205 [TBL] [Abstract][Full Text] [Related]
2. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768 [TBL] [Abstract][Full Text] [Related]
3. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045 [TBL] [Abstract][Full Text] [Related]
4. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. Suzuki K; Sunami K; Matsumoto M; Maki A; Shimada F; Suzuki K; Shimizu K Acta Haematol; 2021; 144(3):264-274. PubMed ID: 33279887 [TBL] [Abstract][Full Text] [Related]
5. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Martin P; Ruan J; Furman R; Rutherford S; Allan J; Chen Z; Huang X; DiLiberto M; Chen-Kiang S; Leonard JP Leuk Lymphoma; 2019 Dec; 60(12):2917-2921. PubMed ID: 31120355 [TBL] [Abstract][Full Text] [Related]
6. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Laubach JP; Liu CJ; Raje NS; Yee AJ; Armand P; Schlossman RL; Rosenblatt J; Hedlund J; Martin M; Reynolds C; Shain KH; Zackon I; Stampleman L; Henrick P; Rivotto B; Hornburg KTV; Dumke HJ; Chuma S; Savell A; Handisides DR; Kroll S; Anderson KC; Richardson PG; Ghobrial IM Clin Cancer Res; 2019 Jan; 25(2):478-486. PubMed ID: 30279233 [TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Hajek R; Pour L; Ozcan M; Martin Sánchez J; García Sanz R; Anagnostopoulos A; Oriol A; Cascavilla N; Terjung A; Lee Y; Briso EM; Dobkowska E; Hauns B; Špička I Eur J Haematol; 2020 May; 104(5):435-442. PubMed ID: 31883396 [TBL] [Abstract][Full Text] [Related]
9. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475 [TBL] [Abstract][Full Text] [Related]
10. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Chari A; Htut M; Zonder JA; Fay JW; Jakubowiak AJ; Levy JB; Lau K; Burt SM; Tunquist BJ; Hilder BW; Rush SA; Walker DH; Ptaszynski M; Kaufman JL Cancer; 2016 Nov; 122(21):3327-3335. PubMed ID: 27433944 [TBL] [Abstract][Full Text] [Related]
11. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Goldschmidt H; Moreau P; Ludwig H; Niesvizky R; Chng WJ; Joshua D; Weisel K; Spencer A; Orlowski RZ; Feng S; Iskander KS; Dimopoulos MA Leuk Lymphoma; 2018 Jun; 59(6):1364-1374. PubMed ID: 28937327 [TBL] [Abstract][Full Text] [Related]
12. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ; Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818 [TBL] [Abstract][Full Text] [Related]
13. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study]. Bao L; Lu XJ; Zhang XH; Huang XJ Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018 [TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. Reece DE; Trieu Y; Masih-Khan E; Atenafu EG; Chen C; Prica A; Tiedemann R; Trudel S; Kukreti V Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):387-94. PubMed ID: 27349765 [TBL] [Abstract][Full Text] [Related]
15. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023 [No Abstract] [Full Text] [Related]
16. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655 [TBL] [Abstract][Full Text] [Related]
17. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Brown S; Pawlyn C; Tillotson AL; Sherratt D; Flanagan L; Low E; Morgan GJ; Williams C; Kaiser M; Davies FE; Jenner MW; Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):154-161.e3. PubMed ID: 33478922 [TBL] [Abstract][Full Text] [Related]
19. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748 [TBL] [Abstract][Full Text] [Related]
20. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]